Erythropoietin and the heart: Physiological effects and the therapeutic perspective

International Journal of Cardiology

Volumn 171, Issue 2, 2014, Pages 116-125

  Sanchis Gomar, Fabian ^a,b   Garcia Gimenez, José Luis ^a,b,c   Pareja Galeano, Helios ^a,b   Romagnoli, Marco ^d   Perez Quilis, Carme ^a,b   Lippi, Giuseppe ^e  

^a UNIVERSITY OF VALENCIA   (Spain)

^b Instituto Universitario IVI INCLIVA   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^d UNIVERSIDAD CATÓLICA DE VALENCIA SAN VICENTE MÁRTIR   (Spain)

^e ACADEMIC HOSPITAL OF PARMA   (Italy)

Author keywords

Angiogenesis; Cardioprotection; EpoR; Inflammation; Myocardial infarction; Remodelling

Indexed keywords

ANTIANEMIC AGENT; ASIALOERYTHROPOIETIN; CARBAMYLATED ERYTHROPOIETIN; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGINESATIDE; PLACEBO; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN BETA; RECOMBINANT ERYTHROPOIETIN DELTA; RECOMBINANT ERYTHROPOIETIN GAMMA; RECOMBINANT ERYTHROPOIETIN OMEGA; RECOMBINANT ERYTHROPOIETIN THETA; RECOMBINANT ERYTHROPOIETIN ZETA; TENECTEPLASE; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ANEMIA; ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; BLOOD CLOTTING DISORDER; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EMBOLISM; FATIGUE; HEART FAILURE; HEART INFARCTION; HEART INFARCTION SIZE; HEART PROTECTION; HEART VENTRICLE REMODELING; HEMATOCRIT; HUMAN; HYPERTENSION; LOW DRUG DOSE; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; POLYCYTHEMIA; PRIORITY JOURNAL; REVIEW; SEIZURE; SEPTIC SHOCK; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYSTOLIC HEART FAILURE; THROMBOCYTE ACTIVATION; THROMBOCYTE DISORDER; THROMBOSIS; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS; CARDIOPROTECTION; EPOR; INFLAMMATION; MYOCARDIAL INFARCTION; REMODELLING;

AIRWAY REMODELING; CARDIOTONIC AGENTS; ERYTHROPOIETIN; HEART; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, ERYTHROPOIETIN;

EID: 84892883422     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.12.011     Document Type: Review

References (164)

1. M. Digicaylioglu, S. Bichet, and H.H. Marti et al. Localization of specific erythropoietin binding sites in defined areas of the mouse brain Proc Natl Acad Sci U S A 92 1995 3717 3720
2. W. Jelkmann Erythropoietin research, 80 years after the initial studies by Carnot and Deflandre Respir Physiol 63 1986 257 266
3. W. Jelkmann Erythropoietin: structure, control of production, and function Physiol Rev 72 1992 449 489
4. V.H. Haase Regulation of erythropoiesis by hypoxia-inducible factors Blood Rev 27 2013 41 53
5. C. Dame, H. Fahnenstich, and P. Freitag et al. Erythropoietin mRNA expression in human fetal and neonatal tissue Blood 92 1998 3218 3225
6. H.H. Marti, R.H. Wenger, and L.A. Rivas et al. Erythropoietin gene expression in human, monkey and murine brain Eur J Neurosci 8 1996 666 676
7. H.H. Marti, M. Gassmann, and R.H. Wenger et al. Detection of erythropoietin in human liquor: intrinsic erythropoietin production in the brain Kidney Int 51 1997 416 418
8. M. Bernaudin, A. Bellail, and H.H. Marti et al. Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain Glia 30 2000 271 278
9. M. Magnanti, O. Gandini, and L. Giuliani et al. Erythropoietin expression in primary rat Sertoli and peritubular myoid cells Blood 98 2001 2872 2874
10. C. Dame, P. Bartmann, and E. Wolber et al. Erythropoietin gene expression in different areas of the developing human central nervous system Brain Res Dev Brain Res 125 2000 69 74
11. J. Fandrey, and H.F. Bunn In vivo and in vitro regulation of erythropoietin mRNA: measurement by competitive polymerase chain reaction Blood 81 1993 617 623
12. E. Bodo, A. Kromminga, and W. Funk et al. Human hair follicles are an extrarenal source and a nonhematopoietic target of erythropoietin FASEB J 21 2007 3346 3354
13. Y. Yasuda, S. Masuda, and M. Chikuma et al. Estrogen-dependent production of erythropoietin in uterus and its implication in uterine angiogenesis J Biol Chem 273 1998 25381 25387
14. T. Kobayashi, H. Yanase, T. Iwanaga, R. Sasaki, and M. Nagao Epididymis is a novel site of erythropoietin production in mouse reproductive organs Biochem Biophys Res Commun 296 2002 145 151
15. S. Masuda, T. Kobayashi, M. Chikuma, M. Nagao, and R. Sasaki The oviduct produces erythropoietin in an estrogen- and oxygen-dependent manner Am J Physiol Endocrinol Metab 278 2000 E1038 E1044
16. E.B. Rankin, C. Wu, and R. Khatri et al. The HIF signaling pathway in osteoblasts directly modulates erythropoiesis through the production of EPO Cell 149 2012 63 74
17. G. Acs, P. Acs, and S.M. Beckwith et al. Erythropoietin and erythropoietin receptor expression in human cancer Cancer Res 61 2001 3561 3565
18. C. Lundby, Y. Hellsten, M.B. Jensen, A.S. Munch, and H. Pilegaard Erythropoietin receptor in human skeletal muscle and the effects of acute and long-term injections with recombinant human erythropoietin on the skeletal muscle J Appl Physiol 104 2008 1154 1160
19. H.E. Broxmeyer Erythropoietin surprises: an immune saga Immunity 34 2011 6 7
20. M. Nairz, A. Schroll, and A.R. Moschen et al. Erythropoietin contrastingly affects bacterial infection and experimental colitis by inhibiting nuclear factor-kappaB-inducible immune pathways Immunity 34 2011 61 74
21. M. Nairz, T. Sonnweber, A. Schroll, I. Theurl, and G. Weiss The pleiotropic effects of erythropoietin in infection and inflammation Microbes Infect 14 2012 238 246
22. M. Brines, and A. Cerami Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise Kidney Int 70 2006 246 250
23. D. Choi, S.A. Schroer, and S.Y. Lu et al. Erythropoietin protects against diabetes through direct effects on pancreatic beta cells J Exp Med 207 2010 2831 2842
24. C.C. Hand, and M. Brines Promises and pitfalls in erythopoietin-mediated tissue protection: are nonerythropoietic derivatives a way forward? J Investig Med 59 2011 1073 1082
25. S.J. McGee, A.M. Havens, Y. Shiozawa, Y. Jung, and R.S. Taichman Effects of erythropoietin on the bone microenvironment Growth Factors 30 2012 22 28
26. A.J. Sytkowski The neurobiology of erythropoietin Cell Mol Neurobiol 31 2011 931 937
27. R. Rotter, M. Menshykova, and T. Winkler et al. Erythropoietin improves functional and histological recovery of traumatized skeletal muscle tissue J Orthop Res 26 2008 1618 1626
28. W. Jelkmann Erythropoietin after a century of research: younger than ever Eur J Haematol 78 2007 183 205
29. C. Lundby, and N.V. Olsen Effects of recombinant human erythropoietin in normal humans J Physiol 589 2011 1265 1271
30. M.S. Carraway, H.B. Suliman, and W.S. Jones et al. Erythropoietin activates mitochondrial biogenesis and couples red cell mass to mitochondrial mass in the heart Circ Res 106 2010 1722 1730
31. J. Cayla, C. Lavoie, R. Gareau, and A. Duvallet Effects of recombinant erythropoietin (r-HuEPO) on plasma glucose concentration in endurance-trained rats Acta Physiol Scand 166 1999 247 249
32. R. Latini, M. Brines, and F. Fiordaliso Do non-hematopoietic effects of erythropoietin play a beneficial role in heart failure? Heart Fail Rev 13 2008 415 423
33. Y. Wen, X.J. Zhang, and Y.X. Ma et al. Erythropoietin attenuates hypertrophy of neonatal rat cardiac myocytes induced by angiotensin-II in vitro Scand J Clin Lab Invest 69 2009 518 525
34. K. Smith, D. Semple, S. Bhandari, and A.M. Seymour Cellular basis of uraemic cardiomyopathy: a role for erythropoietin? Eur J Heart Fail 11 2009 732 738
35. P. van der Meer, E. Lipsic, and R.H. Henning et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction J Am Coll Cardiol 46 2005 125 133
36. D. Nishiya, T. Omura, and K. Shimada et al. Effects of erythropoietin on cardiac remodeling after myocardial infarction J Pharmacol Sci 101 2006 31 39
37. B.D. Westenbrink, F.W. Visser, and A.A. Voors et al. Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well Eur Heart J 28 2007 166 171
38. M. Ogilvie, X. Yu, and V. Nicolas-Metral et al. Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts J Biol Chem 275 2000 39754 39761
39. H. Wu, S.H. Lee, J. Gao, X. Liu, and M.L. Iruela-Arispe Inactivation of erythropoietin leads to defects in cardiac morphogenesis Development 126 1999 3597 3605
40. L. Calvillo, R. Latini, and J. Kajstura et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling Proc Natl Acad Sci U S A 100 2003 4802 4806
41. C. Moon, M. Krawczyk, and D. Ahn et al. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats Proc Natl Acad Sci U S A 100 2003 11612 11617
42. C. Moon, M. Krawczyk, D. Paik, E.G. Lakatta, and M.I. Talan Cardioprotection by recombinant human erythropoietin following acute experimental myocardial infarction: dose response and therapeutic window Cardiovasc Drugs Ther 19 2005 243 250
43. C.J. Parsa, A. Matsumoto, and J. Kim et al. A novel protective effect of erythropoietin in the infarcted heart J Clin Invest 112 2003 999 1007
44. F. Prunier, L. Biere, and M. Gilard et al. Single high-dose erythropoietin administration immediately after reperfusion in patients with ST-segment elevation myocardial infarction: results of the erythropoietin in myocardial infarction trial Am Heart J 163 2012 200 207 [e201]
45. S. Tamareille, N. Ghaboura, and F. Treguer et al. Myocardial reperfusion injury management: erythropoietin compared with postconditioning Am J Physiol Heart Circ Physiol 297 2009 H2035 H2043
46. F. Prunier, O. Pfister, and L. Hadri et al. Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells Am J Physiol Heart Circ Physiol 292 2007 H522 H529
47. E. Lipsic, P. van der Meer, and A.A. Voors et al. A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study Cardiovasc Drugs Ther 20 2006 135 141
48. I. Ott, S. Schulz, and J. Mehilli et al. Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial Circ Cardiovasc Interv 3 2010 408 413
49. A.A. Voors, A.M. Belonje, and F. Zijlstra et al. A single dose of erythropoietin in ST-elevation myocardial infarction Eur Heart J 31 2010 2593 2600
50. S.S. Najjar, S.V. Rao, and C. Melloni et al. Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial JAMA 305 2011 1863 1872
51. Y. Kagaya, Y. Asaumi, and W. Wang et al. Current perspectives on protective roles of erythropoietin in cardiovascular system: erythropoietin receptor as a novel therapeutic target Tohoku J Exp Med 227 2012 83 91
52. A.M. Sinclair, A. Coxon, and I. McCaffery et al. Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells Blood 115 2010 4264 4272
53. S. Elliott, L. Busse, and S. Swift et al. Lack of expression and function of erythropoietin receptors in the kidney Nephrol Dial Transplant 27 2011 2733 2745
54. W. Jelkmann, and S. Elliott Erythropoietin and the vascular wall: the controversy continues Nutr Metab Cardiovasc Dis 23 Suppl. 1 2013 S37 S43
55. J.C. Cheetham, D.M. Smith, and K.H. Aoki et al. NMR structure of human erythropoietin and a comparison with its receptor bound conformation Nat Struct Biol 5 1998 861 866
56. O. Livnah, E.A. Stura, and S.A. Middleton et al. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation Science 283 1999 987 990
57. I. Remy, I.A. Wilson, and S.W. Michnick Erythropoietin receptor activation by a ligand-induced conformation change Science 283 1999 990 993
58. W. Jelkmann Molecular biology of erythropoietin Intern Med 43 2004 649 659
59. B.A. Witthuhn, F.W. Quelle, and O. Silvennoinen et al. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin Cell 74 1993 227 236
60. T. Tauchi, G.S. Feng, and R. Shen et al. Involvement of SH2-containing phosphotyrosine phosphatase Syp in erythropoietin receptor signal transduction pathways J Biol Chem 270 1995 5631 5635
61. D.L. Barber, B.K. Beattie, and J.M. Mason et al. A common epitope is shared by activated signal transducer and activator of transcription-5 (STAT5) and the phosphorylated erythropoietin receptor: implications for the docking model of STAT activation Blood 97 2001 2230 2237
62. P.A. Tilbrook, and S.P. Klinken The erythropoietin receptor Int J Biochem Cell Biol 31 1999 1001 1005
63. U. Klingmuller The role of tyrosine phosphorylation in proliferation and maturation of erythroid progenitor cells - signals emanating from the erythropoietin receptor Eur J Biochem 249 1997 637 647
64. A. Yoshimura, and H. Misawa Physiology and function of the erythropoietin receptor Curr Opin Hematol 5 1998 171 176
65. S.N. Constantinescu, L.J. Huang, H. Nam, and H.F. Lodish The erythropoietin receptor cytosolic juxtamembrane domain contains an essential, precisely oriented, hydrophobic motif Mol Cell 7 2001 377 385
66. H.E. Broxmeyer Erythropoietin: multiple targets, actions, and modifying influences for biological and clinical consideration J Exp Med 210 2013 205 208
67. Y. Zhang, Y. Xiong, and A. Mahmood et al. Therapeutic effects of erythropoietin on histological and functional outcomes following traumatic brain injury in rats are independent of hematocrit Brain Res 1294 2009 153 164
68. E. Lipsic, R.G. Schoemaker, and P. van der Meer et al. Protective effects of erythropoietin in cardiac ischemia: from bench to bedside J Am Coll Cardiol 48 2006 2161 2167
69. X. Shan, X. Xu, and B. Cao et al. Transcription factor GATA-4 is involved in erythropoietin-induced cardioprotection against myocardial ischemia/reperfusion injury Int J Cardiol 134 2009 384 392
70. D.J. Hausenloy, G. Baxter, and R. Bell et al. Translating novel strategies for cardioprotection: the Hatter Workshop Recommendations Basic Res Cardiol 105 2010 677 686
71. J. Rossert, and K.U. Eckardt Erythropoietin receptors: their role beyond erythropoiesis Nephrol Dial Transplant 20 2005 1025 1028
72. K.J. Smith, A.J. Bleyer, W.C. Little, and D.C. Sane The cardiovascular effects of erythropoietin Cardiovasc Res 59 2003 538 548
73. H. Tada, Y. Kagaya, and M. Takeda et al. Endogenous erythropoietin system in non-hematopoietic lineage cells plays a protective role in myocardial ischemia/reperfusion Cardiovasc Res 71 2006 466 477
74. Y. Asaumi, Y. Kagaya, and M. Takeda et al. Protective role of endogenous erythropoietin system in nonhematopoietic cells against pressure overload-induced left ventricular dysfunction in mice Circulation 115 2007 2022 2032
75. L. Wang, M. Chopp, and S.R. Gregg et al. Neural progenitor cells treated with EPO induce angiogenesis through the production of VEGF J Cereb Blood Flow Metab 28 2008 1361 1368
76. R.G. Carlini, A.A. Reyes, and M. Rothstein Recombinant human erythropoietin stimulates angiogenesis in vitro Kidney Int 47 1995 740 745
77. N. Kertesz, J. Wu, T.H. Chen, H.M. Sucov, and H. Wu The role of erythropoietin in regulating angiogenesis Dev Biol 276 2004 101 110
78. A.M. Sinclair Erythropoiesis stimulating agents: approaches to modulate activity Biologics 7 2013 161 174
79. S. Elliott Erythropoiesis-stimulating agents and other methods to enhance oxygen transport Br J Pharmacol 154 2008 529 541
80. J.S. Lee, T.K. Ha, S.J. Lee, and G.M. Lee Current state and perspectives on erythropoietin production Appl Microbiol Biotechnol 95 2012 1405 1416
81. I.C. Macdougall An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP) Nephrol Dial Transplant 16 Suppl. 3 2001 14 21
82. S. Elliott, J. Egrie, and J. Browne et al. Control of rHuEPO biological activity: the role of carbohydrate Exp Hematol 32 2004 1146 1155
83. I.C. Macdougall, S.J. Gray, and O. Elston et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients J Am Soc Nephrol 10 1999 2392 2395
84. F. Locatelli, J. Olivares, and R. Walker et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency Kidney Int 60 2001 741 747
85. J. Glaspy, J.S. Jadeja, and G. Justice et al. A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy Br J Cancer 84 Suppl. 1 2001 17 23
86. W. Jelkmann The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP Eur J Haematol 69 2002 265 274
87. J.C. Egrie, and J.K. Browne Development and characterization of novel erythropoiesis stimulating protein (NESP) Br J Cancer 84 Suppl. 1 2001 3 10
88. R.E. Smith Jr., I.A. Jaiyesimi, and L.A. Meza et al. Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer Br J Cancer 84 Suppl. 1 2001 24 30
89. I.C. Macdougall CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia Curr Hematol Rep 4 2005 436 440
90. V. Hirsh, J. Glaspy, and P. Mainwaring et al. Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy Trials 8 2007 8
91. Q. Fan, K.K. Leuther, and C.P. Holmes et al. Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia Exp Hematol 34 2006 1303 1311
92. K.W. Woodburn, P.J. Schatz, and S. Wilson et al. Genotoxic assessment and toxicity evaluation of peginesatide in CByB6F1 hybrid mice Drug Chem Toxicol 34 2011 240 249
93. K.W. Woodburn, K.L. Fong, and S.D. Wilson et al. Peginesatide clearance, distribution, metabolism, and excretion in monkeys following intravenous administration Drug Metab Dispos 41 2013 774 784
94. A. Liem, A.P. van de Woestijne, and E. Bruijns et al. Effect of EPO administration on myocardial infarct size in patients with non-STE acute coronary syndromes; results from a pilot study Int J Cardiol 131 2009 285 287
95. Y.D. Tang, F. Hasan, and F.J. Giordano et al. Effects of recombinant human erythropoietin on platelet activation in acute myocardial infarction: results of a double-blind, placebo-controlled, randomized trial Am Heart J 158 2009 941 947
96. A.S. Binbrek, N.S. Rao, N. Al Khaja, J. Assaqqaf, and B.E. Sobel Erythropoietin to augment myocardial salvage induced by coronary thrombolysis in patients with ST segment elevation acute myocardial infarction Am J Cardiol 104 2009 1035 1040
97. N. Taniguchi, T. Nakamura, and T. Sawada et al. Erythropoietin prevention trial of coronary restenosis and cardiac remodeling after ST-elevated acute myocardial infarction (EPOC-AMI): a pilot, randomized, placebo-controlled study Circ J 74 2010 2365 2371
98. T. Ozawa, K. Toba, and H. Suzuki et al. Single-dose intravenous administration of recombinant human erythropoietin is a promising treatment for patients with acute myocardial infarction - randomized controlled pilot trial of EPO/AMI-1 study Circ J 74 2010 1415 1423
99. M. Ferrario, E. Arbustini, and M. Massa et al. High-dose erythropoietin in patients with acute myocardial infarction: a pilot, randomised, placebo-controlled study Int J Cardiol 147 2011 124 131
100. J.W. Suh, W.Y. Chung, and Y.S. Kim et al. The effect of intravenous administration of erythropoietin on the infarct size in primary percutaneous coronary intervention Int J Cardiol 149 2011 216 220
101. A.J. Ludman, D.M. Yellon, and J. Hasleton et al. Effect of erythropoietin as an adjunct to primary percutaneous coronary intervention: a randomised controlled clinical trial Heart 97 2011 1560 1565
102. K. Swedberg, J.B. Young, and I.S. Anand et al. Treatment of anemia with darbepoetin alfa in systolic heart failure N Engl J Med 368 2013 1210 1219
103. D. Gao, N. Ning, and X. Niu et al. Erythropoietin treatment in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials Am Heart J 164 2012 715 727 [e711]
104. B.D. Westenbrink, E. Lipsic, and P. van der Meer et al. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization Eur Heart J 28 2007 2018 2027
105. B.D. Westenbrink, W.P. Ruifrok, and A.A. Voors et al. Vascular endothelial growth factor is crucial for erythropoietin-induced improvement of cardiac function in heart failure Cardiovasc Res 87 2010 30 39
106. L. Beck-da-Silva, D. Piardi, and S. Soder et al. IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia Int J Cardiol 168 2013 3439 3442
107. P. Ponikowski, S.D. Anker, and J. Szachniewicz et al. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial J Am Coll Cardiol 49 2007 753 762
108. D.J. van Veldhuisen, K. Dickstein, and A. Cohen-Solal et al. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia Eur Heart J 28 2007 2208 2216
109. J.K. Ghali, I.S. Anand, and W.T. Abraham et al. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia Circulation 117 2008 526 535
110. L. Kleijn, B.D. Westenbrink, and P. van der Meer Erythropoietin and heart failure: the end of a promise? Eur J Heart Fail 15 2013 479 481
111. D.M. Mancini, S.D. Katz, and C.C. Lang et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure Circulation 107 2003 294 299
112. E. Lipsic, B.D. Westenbrink, and P. van der Meer et al. Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit Eur J Heart Fail 10 2008 22 29
113. J.J. McMurray, I.S. Anand, and R. Diaz et al. Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a phase III, anaemia correction, morbidity-mortality trial Eur J Heart Fail 11 2009 795 801
114. V. Campuzano, L. Montermini, and M.D. Molto et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion Science 271 1996 1423 1427
115. A. Durr, M. Cossee, and Y. Agid et al. Clinical and genetic abnormalities in patients with Friedreich's ataxia N Engl J Med 335 1996 1169 1175
116. J.S. Child, J.K. Perloff, and P.M. Bach et al. Cardiac involvement in Friedreich's ataxia: a clinical study of 75 patients J Am Coll Cardiol 7 1986 1370 1378
117. J.L. Garcia-Gimenez, F. Sanchis-Gomar, and F.V. Pallardo Could thiazolidinediones increase the risk of heart failure in Friedreich's ataxia patients? Mov Disord 26 2011 769 771
118. F. Acquaviva, I. Castaldo, and A. Filla et al. Recombinant human erythropoietin increases frataxin protein expression without increasing mRNA expression Cerebellum 7 2008 360 365
119. F. Sacca, R. Piro, and G. De Michele et al. Epoetin alfa increases frataxin production in Friedreich's ataxia without affecting hematocrit Mov Disord 26 2011 739 742
120. S. Boesch, B. Sturm, and S. Hering et al. Neurological effects of recombinant human erythropoietin in Friedreich's ataxia: a clinical pilot trial Mov Disord 23 2008 1940 1944
121. B. Sturm, M. Helminger, and H. Steinkellner et al. Carbamylated erythropoietin increases frataxin independent from the erythropoietin receptor Eur J Clin Invest 40 2010 561 565
122. S. Boesch, B. Sturm, and S. Hering et al. Friedreich's ataxia: clinical pilot trial with recombinant human erythropoietin Ann Neurol 62 2007 521 524
123. W. Nachbauer, J. Wanschitz, and H. Steinkellner et al. Correlation of frataxin content in blood and skeletal muscle endorses frataxin as a biomarker in Friedreich ataxia Mov Disord 26 2011 1935 1938
124. W. Nachbauer, S. Hering, and M. Seifert et al. Effects of erythropoietin on frataxin levels and mitochondrial function in Friedreich ataxia - a dose-response trial Cerebellum 10 2011 763 769
125. W. Nachbauer, S. Boesch, and M. Reindl et al. Skeletal muscle involvement in Friedreich ataxia and potential effects of recombinant human erythropoietin administration on muscle regeneration and neovascularization J Neuropathol Exp Neurol 71 2012 708 715
126. Z.H. Wang, Y.X. Chen, and C.M. Zhang et al. Intermittent hypobaric hypoxia improves postischemic recovery of myocardial contractile function via redox signaling during early reperfusion Am J Physiol Heart Circ Physiol 301 2011 H1695 H1705
127. W.Q. Xu, Z. Yu, and Y. Xie et al. Therapeutic effect of intermittent hypobaric hypoxia on myocardial infarction in rats Basic Res Cardiol 106 2011 329 342
128. F. Sanchis-Gomar, and G. Lippi Erythropoietin and myocardial infarction Clin Transl Sci 4 2011 478
129. F. Sanchis-Gomar, J. Viña, and G. Lippi Intermittent Hypobaric Hypoxia applicability in myocardial infarction prevention and recovery J Cell Mol Med 16 2012 1150 1154
130. T. Xanthos, P.V. Vasileiou, S. Kakavas, A. Syggelou, and N. Iacovidou The potential role of erythropoietin as a pleiotropic agent in post-cardiac arrest syndrome Curr Pharm Des 17 2011 1517 1529
131. M. Kowalczyk, M. Banach, D.P. Mikhailidis, and J. Rysz Erythropoietin update 2011 Med Sci Monit 17 2011 RA240 RA247
132. V. Mastromarino, M. Volpe, M.B. Musumeci, C. Autore, and E. Conti Erythropoietin and the heart: facts and perspectives Clin Sci (Lond) 120 2010 51 63
133. O. Barroso, I. Mazzoni, and O. Rabin Hormone abuse in sports: the antidoping perspective Asian J Androl 10 2008 391 402
134. A. Lubas, G. Zelichowski, and A. Prochnicka et al. Renal vascular response to angiotensin II inhibition in intensive antihypertensive treatment of essential hypertension Arch Med Sci 6 2010 533 538
135. M. Banach, S.E. Kjeldsen, and K. Narkiewicz Controversies in hypertension treatment Curr Vasc Pharmacol 8 2010 731 732
136. J.V. Brugniaux, V. Pialoux, and G.E. Foster et al. Effects of intermittent hypoxia on erythropoietin, soluble erythropoietin receptor and ventilation in humans Eur Respir J 37 2011 880 887
137. R.W. Mackenzie, P.W. Watt, and N.S. Maxwell Acute normobaric hypoxia stimulates erythropoietin release High Alt Med Biol 9 2008 28 37
138. F. Sanchis-Gomar, V.E. Martinez-Bello, and E. Domenech et al. Effect of intermittent hypoxia on hematological parameters after recombinant human erythropoietin administration Eur J Appl Physiol 107 2009 429 436
139. V.E. Martinez-Bello, F. Sanchis-Gomar, and A.L. Nascimento et al. Living at high altitude in combination with sea-level sprint training increases hematological parameters but does not improve performance in rats Eur J Appl Physiol 111 2011 1147 1156
140. G. Greenberg, A. Assali, and H. Vaknin-Assa et al. Hematocrit level as a marker of outcome in ST-segment elevation myocardial infarction Am J Cardiol 105 2010 435 440
141. G. Lippi, and M. Franchini Intermittent hypoxic training: doping or what? Eur J Appl Physiol 108 2010 411 412
142. G. Lippi, M. Franchini, and G.C. Guidi Prohibition of artificial hypoxic environments in sports: health risks rather than ethics Appl Physiol Nutr Metab 32 2007 1206 1207 [discussion 1208-1209]
143. G. Lippi, M. Franchini, and G. Targher Arterial thrombus formation in cardiovascular disease Nat Rev Cardiol 8 2011 502 512
144. T. Takeyama, G. Takemura, and H. Kanamori et al. Asialoerythropoietin, a nonerythropoietic derivative of erythropoietin, displays broad anti-heart failure activity Circ Heart Fail 5 2012 274 285
145. A. Ogino, G. Takemura, and M. Kawasaki et al. Erythropoietin receptor signaling mitigates renal dysfunction-associated heart failure by mechanisms unrelated to relief of anemia J Am Coll Cardiol 56 2010 1949 1958
146. R.A. De Boer, Y.M. Pinto, and D.J. Van Veldhuisen The imbalance between oxygen demand and supply as a potential mechanism in the pathophysiology of heart failure: the role of microvascular growth and abnormalities Microcirculation 10 2003 113 126
147. T. Yanagawa, K. Toba, and K. Kato et al. Asialoerythropoietin exerts stronger angiogenic activity than erythropoietin via its binding affinity to tissue Cardiovasc Drugs Ther 27 2013 117 124
148. S. Carelli, G. Marfia, A.M. Di Giulio, G. Ghilardi, and A. Gorio Erythropoietin: recent developments in the treatment of spinal cord injury Neurol Res Int 2011 2011 453179
149. F. Fiordaliso, S. Chimenti, and L. Staszewsky et al. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury Proc Natl Acad Sci U S A 102 2005 2046 2051
150. P. Villa, J. van Beek, and A.K. Larsen et al. Reduced functional deficits, neuroinflammation, and secondary tissue damage after treatment of stroke by nonerythropoietic erythropoietin derivatives J Cereb Blood Flow Metab 27 2007 552 563
151. A. Mahmood, D. Lu, and C. Qu et al. Treatment of traumatic brain injury in rats with erythropoietin and carbamylated erythropoietin J Neurosurg 107 2007 392 397
152. Y. Wang, Z.G. Zhang, and K. Rhodes et al. Post-ischemic treatment with erythropoietin or carbamylated erythropoietin reduces infarction and improves neurological outcome in a rat model of focal cerebral ischemia Br J Pharmacol 151 2007 1377 1384
153. T.R. Coleman, C. Westenfelder, and F.E. Togel et al. Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities Proc Natl Acad Sci U S A 103 2006 5965 5970
154. P. van der Meer, E. Lipsic, and D.J. van Veldhuisen Asialoerythropoietin to protect the failing heart: is it possible to run with the hare and hunt with the hounds? J Am Coll Cardiol 56 2010 1959 1960
155. D. Burger, M. Lei, and N. Geoghegan-Morphet et al. Erythropoietin protects cardiomyocytes from apoptosis via up-regulation of endothelial nitric oxide synthase Cardiovasc Res 72 2006 51 59
156. F. Treguer, E. Donal, and S. Tamareille et al. Speckle tracking imaging improves in vivo assessment of EPO-induced myocardial salvage early after ischemia-reperfusion in rats Am J Physiol Heart Circ Physiol 298 2009 H1679 H1686
157. F.D. Olea, G. Vera Janavel, and A. De Lorenzi et al. High-dose erythropoietin has no long-term protective effects in sheep with reperfused myocardial infarction J Cardiovasc Pharmacol 47 2006 736 741
158. J. Kristensen, M. Maeng, and M. Rehling et al. Lack of acute cardioprotective effect from preischaemic erythropoietin administration in a porcine coronary occlusion model Clin Physiol Funct Imaging 25 2005 305 310
159. N.P. Riksen, D.J. Hausenloy, and D.M. Yellon Erythropoietin: ready for prime-time cardioprotection Trends Pharmacol Sci 29 2008 258 267
160. M.I. Talan, I. Ahmet, and E.G. Lakatta Did clinical trials in which erythropoietin failed to reduce acute myocardial infarct size miss a narrow therapeutic window? PLoS One 7 2012 e34819
161. A.F. Cicero, and S. Ertek Preclinical and clinical evidence of nephro- and cardiovascular protective effects of glycosaminoglycans Arch Med Sci 6 2010 469 477
162. O. Durmaz, M. Demirkaya, and B. Sevinir Recombinant human erythropoietin beta: the effect of weekly dosing on anemia, quality of life, and long-term outcomes in pediatric cancer patients Pediatr Hematol Oncol 28 2011 461 468
163. A. Osterborg New erythropoietic proteins: rationale and clinical data Semin Oncol 31 2004 12 18
164. I.C. Macdougall, D. Padhi, and G. Jang Pharmacology of darbepoetin alfa Nephrol Dial Transplant 22 Suppl. 4 2007 iv2 iv9